ALK-Abelló A/S - Asset Resilience Ratio

Latest as of September 2019: 0.98%

ALK-Abelló A/S (ALK-B) has an Asset Resilience Ratio of 0.98% as of September 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ALK-B total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

Dkr50.00 Million

≈ $7.82 Million USD Cash + Short-term Investments

Total Assets

Dkr5.09 Billion

≈ $796.52 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2007–2019)

This chart shows how ALK-Abelló A/S's Asset Resilience Ratio has changed over time. See shareholders equity of ALK-Abelló A/S for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down ALK-Abelló A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ALK-Abelló A/S market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Dkr0.00	0%
Short-term Investments	Dkr50.00 Million	0.98%
Total Liquid Assets	Dkr50.00 Million	0.98%

Asset Resilience Insights

Limited Liquidity: ALK-Abelló A/S maintains only 0.98% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

ALK-Abelló A/S Industry Peers by Asset Resilience Ratio

Compare ALK-Abelló A/S's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Argen-X F:1AE	Biotechnology	25.67%
Zhejiang Ausun Pharmaceutical Co Ltd SHG:603229	Biotechnology	0.21%
R&G PharmaStudies Co. Ltd. A SHE:301333	Biotechnology	35.96%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	79.48%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	70.49%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%

Annual Asset Resilience Ratio for ALK-Abelló A/S (2007–2019)

The table below shows the annual Asset Resilience Ratio data for ALK-Abelló A/S.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2019-12-31	-2.91%	Dkr-160.00 Million ≈ $-25.03 Million	Dkr5.50 Billion ≈ $859.73 Million	-4.97pp
2018-12-31	2.06%	Dkr100.00 Million ≈ $15.65 Million	Dkr4.87 Billion ≈ $761.16 Million	-9.02pp
2017-12-31	11.07%	Dkr549.00 Million ≈ $85.90 Million	Dkr4.96 Billion ≈ $775.72 Million	-0.35pp
2016-12-31	11.42%	Dkr548.00 Million ≈ $85.74 Million	Dkr4.80 Billion ≈ $750.84 Million	+1.26pp
2015-12-31	10.16%	Dkr432.00 Million ≈ $67.59 Million	Dkr4.25 Billion ≈ $665.26 Million	+4.08pp
2014-12-31	6.08%	Dkr208.00 Million ≈ $32.54 Million	Dkr3.42 Billion ≈ $534.93 Million	-9.09pp
2007-12-31	15.17%	Dkr428.00 Million ≈ $66.96 Million	Dkr2.82 Billion ≈ $441.37 Million	--

pp = percentage points

About ALK-Abelló A/S

CO:ALK-B Denmark Biotechnology

Market Cap

$7.62 Billion

Dkr48.72 Billion DKK

Market Cap Rank

#2704 Global

#15 in Denmark

Share Price

Dkr242.00

Change (1 day)

+1.51%

52-Week Range

Dkr159.00 - Dkr242.00

All Time High

Dkr242.00